Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corporation (Nasdaq: ABSI) is a clinical-stage biopharmaceutical and biotechnology company that frequently issues news related to its generative AI-driven drug discovery platform and internal pipeline of biologic therapeutics. News coverage for Absci often centers on developments in its lead AI-designed antibody programs, platform collaborations, and corporate updates that are relevant to investors and the broader life sciences community.
A major focus of recent Absci news is ABS-201™, an anti-prolactin receptor (PRLR) antibody being developed for androgenetic alopecia and investigated for endometriosis. Press releases have described preclinical human ex vivo data on hair growth, the design and initiation of the Phase 1/2a HEADLINE trial in androgenetic alopecia, and plans for Phase 2 development in endometriosis. Updates also highlight scientific advisory board appointments, key opinion leader seminars, and partnerships aimed at elevating patient perspectives in hair loss research.
Investors following ABSI news can also expect announcements on pipeline progress for programs such as ABS-101, ABS-301, and ABS-501, as well as drug creation partnerships with pharmaceutical, biotech, technology, and academic organizations. Absci has reported collaborations with cloud and hardware providers to support its AI Drug Creation platform, along with participation in healthcare and biotech investor conferences and major industry events.
This news feed aggregates Absci’s press releases and third-party coverage, including items on clinical trial milestones, scientific data presentations, financing and capital markets activity, and corporate governance changes. Readers interested in ABSI can use this page to monitor how Absci’s AI-enabled platform, internal therapeutic programs, and partnerships evolve over time and to track key events that may shape the company’s scientific and business trajectory.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York. The company's Founder & CEO Sean McClain will join a panel discussion on 'The Promise of AI in Drug Development' scheduled for Thursday, December 5th at 2:00 p.m. Eastern Time. Those interested in attending can request registration details through their Piper Sandler representative.
Absci (ABSI) reported Q3 2024 financial results and business updates. Revenue increased to $1.7 million from $0.7 million year-over-year. Net loss widened to $27.4 million from $22.0 million in Q3 2023. The company delivered AI-designed antibody sequences to AstraZeneca, meeting their first milestone, and entered a new collaboration with Twist Bioscience. R&D expenses increased to $18.0 million from $11.0 million YoY. Cash position stands at $127.1 million, expected to fund operations into first half of 2027. The company reduced its expected cash use for 2024 to $75 million from $80 million previously.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its upcoming 2024 R&D Day scheduled for December 12th in New York City. The event will run from 9:00 a.m. to approximately 12:00 p.m. Eastern Time, featuring presentations from Absci's leadership team and guest speakers, followed by an interactive Q&A session. Interested participants can access both live and archived webcasts of the event through the company's investor relations website at investors.absci.com.
Absci (NASDAQ: ABSI) and Twist Bioscience announced a collaboration to design a novel therapeutic using generative AI. The partnership combines Absci's AI drug creation platform with Twist's DNA synthesis technology to accelerate pharmaceutical R&D. The companies will develop a therapeutic candidate against an undisclosed target, utilizing Absci's AI de novo design capabilities and Twist's silicon-based synthesis platform, including Multiplexed Gene Fragments for testing antibody candidates. Both companies plan to seek a partner for clinical development and commercialization. This program adds to Absci's portfolio of collaborations with companies like AstraZeneca and Merck.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in multiple investor conferences in November 2024. The schedule includes the Truist Securities BioPharma Symposium in New York, Guggenheim Securities Inaugural Healthcare Innovation Conference in Boston, UBS Global Healthcare Conference in California, Stifel 2024 Healthcare Conference in New York, and Jefferies London Healthcare Conference in the UK. The company will participate in fireside chats and host one-on-one meetings. Live and archived webcasts will be available on Absci's investor relations website.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced it will report business updates and financial and operating results for the third quarter of 2024 before market open on Tuesday, November 12, 2024. The company's management will host a conference call and webcast at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time on the same day to discuss developments, results, and outlook.
Investors can access the live audio webcast on Absci's investor relations website at investors.absci.com. The webcast will also be archived for later replay. This announcement indicates Absci's commitment to transparency and shareholder communication, providing an opportunity for investors to gain insights into the company's performance and future prospects.
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in three upcoming investor conferences in September 2024:
- Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5th at 5:35 p.m. ET
- Citi 2024 Global TMT Conference: Fireside chat on September 6th at 8:20 a.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on September 10th at 12:00 p.m. ET
Interested parties can access live and archived webcasts of these events on Absci's investor relations website at investors.absci.com.
Absci (Nasdaq: ABSI) reported Q2 2024 financial results and business updates. Key highlights include:
1. Non-human primate studies for ABS-101 showed 2-3x extended half-life compared to antibodies in clinical development.
2. Collaboration with Memorial Sloan Kettering Cancer Center to develop up to six novel oncology therapeutics.
3. Revenue decreased to $1.3 million from $3.4 million in Q2 2023.
4. Net loss reduced to $24.8 million from $41.7 million in Q2 2023.
5. Cash position of $145.2 million as of June 30, 2024.
6. Company expects to initiate Phase 1 clinical studies for ABS-101 in early 2025.
Absci (Nasdaq: ABSI) has announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to discover and develop up to six novel cancer therapeutics using generative AI. This partnership combines Absci's Integrated Drug Creation™ platform with MSK's renowned cancer research expertise. The collaboration aims to advance cancer research and develop new therapies for patients.
This initiative adds to Absci's growing list of research and drug development collaborations, including partnerships with AstraZeneca, Almirall, Merck, and NVIDIA. Absci is also developing its own pipeline of drug candidates, such as ABS-101, a potential best-in-class anti-TL1A antibody designed using generative AI.
Absci (Nasdaq: ABSI), a leader in generative AI for drug creation, will release its second-quarter 2024 financial and operating results on August 14, 2024, after market close. The announcement will include business updates and financial performance. A follow-up conference call is scheduled for 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Investors can access the live audio webcast on Absci's investor relations website, with an archived replay available post-event.